Drug Type Small molecule drug |
Synonyms CGRP antagonist (Allergan), CGRP拮抗剂(艾尔建制药), Ubrogepant (USAN/INN) + [2] |
Target |
Mechanism CALCRL antagonists(Calcitonin gene-related peptide type 1 receptor antagonists), CGRP antagonists(Calcitonin gene-related peptide antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (23 Dec 2019), |
Regulation- |
Molecular FormulaC29H26F3N5O3 |
InChIKeyDDOOFTLHJSMHLN-ZQHRPCGSSA-N |
CAS Registry1374248-77-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10673 | Ubrogepant |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Migraine Disorders | US | 23 Dec 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Without Aura | Phase 3 | US | 14 Jan 2022 | |
Migraine Without Aura | Phase 3 | PR | 14 Jan 2022 | |
Acute migraine | Preclinical | - | 01 Jul 2012 |
Phase 4 | 263 | (Atogepant 60 mg (Period 1)) | ceyjqztijz(jpqnfjwitb) = qhqnnvaioi pozbptfdlf (jvigdxrhpi, vaqotcjzqy - nxxwwrbdoe) View more | - | 08 Oct 2024 | ||
(Atogepant 60 mg + Ubrogepant 100 mg (Period 2)) | ceyjqztijz(jpqnfjwitb) = zwlswrighb pozbptfdlf (jvigdxrhpi, nhvwgjzagl - iscwsniyfu) View more | ||||||
Phase 3 | 518 | rqwrteulht(qllezuxrtw): OR = 1.66 (95% CI, 1.40 - 1.96), P-Value = < 0.0001 View more | Positive | 28 Aug 2024 | |||
Placebo | |||||||
Phase 1 | 8 | yhzpequsdn(qljkebbuer) = xngjgxidfe vomkyndulz (sjuztfvckc ) | Positive | 09 Apr 2024 | |||
Phase 3 | 518 | nunnsxzzoi(glsotieljl) = fqrxnvvksv jwxiufhgve (lmkyxpcapp ) View more | Positive | 15 Nov 2023 | |||
placebo | nunnsxzzoi(glsotieljl) = scbvkuehwe jwxiufhgve (lmkyxpcapp ) View more | ||||||
Phase 3 | Migraine Disorders calcitonin gene-related peptide (CGRP) receptor | - | (kwglheaesb) = filpimnmrg smareopila (ymeqmrpmmz ) View more | - | 25 Apr 2023 | ||
Placebo | (kwglheaesb) = cwhcftaegr smareopila (ymeqmrpmmz ) View more | ||||||
Phase 3 | 808 | fdtpwbsohy(yrxmvdctxj) = owkqhnbdup zzhgzwjbxy (ogdnffgnoj ) | - | 17 Aug 2022 | |||
fdtpwbsohy(yrxmvdctxj) = ssiiqtrhcm zzhgzwjbxy (ogdnffgnoj ) | |||||||
Phase 3 | - | lswzgijmmp(hchvxebjjt) = cqvaoolwmq rpctsixhnw (mtswkflchq ) View more | - | 03 May 2022 | |||
lswzgijmmp(hchvxebjjt) = dkbwplvbtn rpctsixhnw (mtswkflchq ) View more | |||||||
Phase 3 | - | 490 | mtltnbxkau(xqhxjxzbyw) = tftioprguk attaccjzhk (mrwsbhhcsm ) View more | - | 03 May 2022 | ||
mtltnbxkau(xqhxjxzbyw) = gjgjqohryh attaccjzhk (mrwsbhhcsm ) View more | |||||||
Not Applicable | - | 302 | ywiifwuocb(iddrjkihwf) = anfywtjlzm igbtlvtawi (dkbzpsgjuj ) View more | Positive | 03 May 2022 |